Biological Safety Support throughout the Medical Device Lifecycle
Is your Biological Evaluation Documentation ready for the latest ISO 10993 expectations? Biological safety is not a one-time regulatory activity. Throughout the medical device lifecycle, manufacturers must continually assess whether existing biological safety evidence remains sufficient as standards evolve and devices, materials, suppliers, and processes change. Regulatory expectations continue to evolve throughout the medical device […]
Welcome Gunilla Landin, our new Senior QA/RA Consultant
Gunilla Landin has recently joined GBA Key2Compliance as our new Senior QA/RA Consultant. With extensive experience in regulatory affairs across both pharmaceuticals and medical devices, Gunilla brings valuable knowledge and a broad perspective to our team. Gunilla is a pharmacist by training and has worked within regulatory affairs for most of her professional career. She […]
Webinar – Is your AI software a medical device?
Artificial Intelligence is transforming healthcare, but determining whether your AI solution qualifies as a medical device can be challenging. Join our free upcoming webinar to gain a clearer understanding of the regulatory landscape for AI-based software. We will explore qualification and classification under medical device regulations, applicable laws and standards, and the pathway to market. […]
A New ISO Standard for IVD Performance Evaluation Is Taking Shape
Performance evaluation is central to demonstrating conformity under the EU IVDR. To date manufacturers have typically established their performance evaluation frameworks by drawing on the Regulation, MDCG guidance and several standards addressing individual parts of the evidence lifecycle. A new ISO project, currently under development, may eventually provide a more consolidated international reference for performance […]
Own-Brand Distribution Under MDR/IVDR: Who May Assign the UDI-DI?
Anna SahlholmConsultant manager, GBA Key2Compliance When the same medical device is sold under different trade names, it may seem logical for each brand owner to obtain its own UDI-DI. Under the EU MDR and IVDR, however, the decisive question is not who owns the brand, but who acts as the legal manufacturer. MDCG 2026-5 addresses […]